Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
暂无分享,去创建一个
H. Schumacher | R. Wortmann | Denise Eustace | P. Macdonald | M. Becker | L. Vernillet | W. Palo | N. Joseph‐Ridge